Analysts Issue Forecasts for UCB SA’s FY2023 Earnings (OTCMKTS:UCBJF)

UCB SA (OTCMKTS:UCBJF – Get Rating) – Analysts at Jefferies Financial Group decreased their FY2023 earnings per share estimates for UCB in a research report issued on Wednesday, March 15th. Jefferies Financial Group analyst P. Welford now expects that the company will post earnings of $4.05 per share for the year, down from their previous forecast of $4.61. The consensus estimate for UCB’s current full-year earnings is $3.83 per share. Jefferies Financial Group also issued estimates for UCB’s FY2024 earnings at $5.48 EPS, FY2025 earnings at $7.76 EPS and FY2026 earnings at $8.67 EPS.

A number of other equities research analysts also recently issued reports on the company. Morgan Stanley downgraded UCB from an “equal weight” rating to an “underweight” rating in a research report on Monday, December 5th. Barclays upgraded UCB from an “equal weight” rating to an “overweight” rating in a research report on Monday, December 5th. Finally, JPMorgan Chase & Co. cut their target price on UCB from €120.00 ($129.03) to €105.00 ($112.90) in a research note on Monday, December 5th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $99.57.

UCB Stock Performance

OTCMKTS:UCBJF opened at $84.42 on Friday. UCB has a 12 month low of $68.30 and a 12 month high of $122.90. The business’s 50-day moving average is $82.17 and its 200 day moving average is $77.08.

About UCB

(Get Rating)

UCB SA engages in the research and development biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.